Compare Cytokinetics Inc (CYTK) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Keysight Technologies Inc — how do they compare? Cytokinetics Inc trades at $62.85 (market cap $8.62B), while Keysight Technologies Inc trades at $375.53 (market cap $63.79B). The key difference: Keysight Technologies Inc is far larger — about 7.4× Cytokinetics Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Keysight Technologies Inc for 56 Days on average.
| CYTK | KEYS | |
|---|---|---|
Market Cap | $8.62B | $63.79B |
Volume | 2,594,626 | 1,435,384 |
Sector | Health | Technology |
52-Week High | $87.26 | $387.90 |
52-Week Low | $54.76 | $159.49 |
Typical Hold Time | 19 Days | 56 Days |
Enterprise Value | $8.72B | $63.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
KEYS trades at $381.49, down 1.65% on the day, with a bullish technical signal from moving averages and strong fundamental performance including three consecutive quarterly earnings beats. Revenue for 2025 reached $5.38 billion with a net income margin of 19.14%, while analyst consensus is strongly bullish with an 81.25% buy rating and a $416.63 price target. Recent news highlights growth in AI infrastructure and 6G technology development.
The outlook for KEYS is positive, driven by accelerating earnings and expanding AI and 6G opportunities, though high valuation multiples and supply chain constraints present risks. Upside potential exists if the company continues to exceed earnings expectations and capitalize on tech sector demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
